Nanocis (Rhenium Sulfide)

Rhenium sulfide, the active ingredient in Nanocis, is a chemical compound presented as a pharmaceutical grade material for oral and subcutaneous administration. It is currently being studied for potential therapeutic applications in various disease models, although no specific approved indications have been established to date.

GNH USA supplies Nanocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Nanocis (Rhenium sulfide) currently has no established therapeutic indications.

- No approved indication: under clinical investigation for potential therapeutic use.

Adverse reactions associated with Nanocis (Rhenium sulfide) have not been fully characterized in clinical studies.

Common Side Effects: - None reported: insufficient clinical data.

Serious or Rare Side Effects: - None reported: insufficient clinical data.

Given the limited data on Nanocis, precautionary measures are recommended.

- Medical supervision: use only under qualified healthcare professional guidance. - Allergy assessment: discontinue if hypersensitivity reactions occur. - Renal function: monitor in patients with impaired kidney function. - Pregnancy and lactation: avoid use due to unknown safety. - Store at ambient temperature: keep in original container, protect from moisture and light.

Potential drug interactions with Nanocis have not been systematically studied.

Major Interactions (Avoid): - None identified: insufficient data.

Moderate Interactions (Monitor Closely): - None identified: insufficient data.